Clinical data | |
---|---|
Trade names | Alhemo |
Pregnancy category |
|
Routes of administration | Subcutaneous |
Drug class | Antihemorrhagic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6462H10004N1712O2046S46 |
Molar mass | 145887.81 g·mol−1 |
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.[4] It is an anti-tissue factor pathway inhibitor.[4]
Concizumab was approved for medical use in Canada in March 2023.[3][6]
Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[4][5]
Concizumab is the international nonproprietary name.[7]